These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

942 related articles for article (PubMed ID: 24517065)

  • 1. [Effect of Erigeron Breviscapus on the expression of OPG/RANKL/RANK in osteoblasts and pre-osteoclasts in vitro].
    Liu CG; Luo QX; Ling TY; Mo YY; Cheng ZL; Huang SG; Mo H
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Dec; 33(12):1658-64. PubMed ID: 24517065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The function of bushen qiangdu recipe containing serum in OPG/RANKL pathway of ankylosing spondylitis patients].
    Xu Y; Ya XP; Zhang WJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):521-4. PubMed ID: 22803436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establish mouse osteoblast -osteoclast cell co-culture system in a Transwell chamber].
    Mo GY; Zhang SC; Li YX; Guo HZ; Guo DQ; Li DX; Tang YC; Mo L; Luo PJ; Ma YH
    Zhongguo Gu Shang; 2018 Mar; 31(3):241-247. PubMed ID: 29600675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zebrafish scales respond differently to in vitro dynamic and static acceleration: analysis of interaction between osteoblasts and osteoclasts.
    Kitamura K; Takahira K; Inari M; Satoh Y; Hayakawa K; Tabuchi Y; Ogai K; Nishiuchi T; Kondo T; Mikuni-Takagaki Y; Chen W; Hattori A; Suzuki N
    Comp Biochem Physiol A Mol Integr Physiol; 2013 Sep; 166(1):74-80. PubMed ID: 23632157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Wenyangbushen formula on the expression of VEGF, OPG, RANK and RANKL in rabbits with steroid-induced femoral head avascular necrosis.
    Song HM; Wei YC; Li N; Wu B; Xie N; Zhang KM; Wang SZ; Wang HM
    Mol Med Rep; 2015 Dec; 12(6):8155-61. PubMed ID: 26496816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity.
    Irie A; Takami M; Kubo H; Sekino-Suzuki N; Kasahara K; Sanai Y
    Bone; 2007 Aug; 41(2):165-74. PubMed ID: 17560185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
    Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
    J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
    Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
    Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
    Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
    Liu XH; Kirschenbaum A; Yao S; Levine AC
    Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG.
    Aoyama E; Kubota S; Khattab HM; Nishida T; Takigawa M
    Bone; 2015 Apr; 73():242-8. PubMed ID: 25554597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway.
    Shen Y; Jiang T; Wang R; He S; Guo M; Zuo J; He D
    BMC Complement Altern Med; 2015 Mar; 15():77. PubMed ID: 25887296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [In vitro induction studies of YouGui drink on culture of steroid induced necrosis of femoral head rat osteoblast].
    Tong PJ; Xu L; Hu BS; Jin HT; Li TY; Fang X
    Zhongguo Gu Shang; 2010 Jan; 23(1):23-7. PubMed ID: 20191959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
    Cao J; Venton L; Sakata T; Halloran BP
    J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.
    Kwan Tat S; Pelletier JP; Lajeunesse D; Fahmi H; Lavigne M; Martel-Pelletier J
    Clin Exp Rheumatol; 2008; 26(2):295-304. PubMed ID: 18565252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation.
    Lee SK; Lorenzo JA
    Endocrinology; 1999 Aug; 140(8):3552-61. PubMed ID: 10433211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.